Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@genomenon.com

NCT ID NCT01609556
Title First-in-Human Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of IMGN853 in Adults With Ovarian Cancer and Other FOLR1-Positive Solid Tumors
Acronym IMGN853-0401
Recruitment Completed
Gender both
Phase Phase I
Variant Requirements No
Sponsors ImmunoGen, Inc.
Indications
Therapies
Age Groups: senior | adult
Covered Countries USA | CAN


No variant requirements are available.